Scott Gottlieb notes the chilling effect of current DOJ policy. I still think he underestimates the incentives facing prosecutors and pharmaceutical companies in hoping for internal reform or successful pharmaceutical-company challenges; reform is going to have to come from the legislature or from higher up in the executive branch, and neither is likely in this administration or in a media environment that views pharmaceutical companies as evils to be barely tolerated rather than the major driver of healthcare innovation.
More on Caronia
- Accutane recusal motion update
- Ninth Circuit refuses to extend Caronia
- Are big-bank prosecutions following in the troubled footsteps of FCPA enforcement?
- Ahmed v. McDonald's
- Opponents of mass incarceration may have an unlikely friend in "Broken Windows."
- FDA won't appeal off-label promotion ruling
- "Ham Sandwich Nation: Due Process When Everything is a Crime"
- Committing bribery without knowing it
- New Report: The world's policeman in FCPA enforcement
- Aaron Swartz and overcriminalization
- Why does FDA keep drugmakers from informing doctors?
- Overcriminalization and CEO pay
- More on Higbee recusal motion in Accutane litigation
- United States v. Caronia
Center for Legal Policy at the